Peptide-Based Nanocarrier Delivers Anti-Cancer Gene Therapy to Breast Cancer Cells

The MiRGD peptide nanocarrier was expressed in E. coli and purified using Ni-NTA affinity chromatography. MCF7 breast cancer cells were transfected with the htsFLT01/MiRGD nanocomplex at an N/P ratio of 14 (previously optimized). Cell lysates were collected and analyzed for expression of apoptosis-related genes (FADD, CASP8, TP53) using gene expression analysis. Statistical analysis was performed using SPSS and REST 2009 software.

Effective cancer gene therapy requires both a therapeutic gene and a safe, efficient delivery system. Peptide-based carriers like MiRGD offer advantages over viral vectors in terms of safety and biocompatibility. The finding that this system activates both anti-angiogenic and apoptotic pathways simultaneously could make it more effective than single-mechanism approaches.

Peptide-based nanocarriers are an active area of cancer therapy research, offering the potential for targeted delivery with lower toxicity than viral vectors or synthetic nanoparticles. This study demonstrates that combining anti-angiogenic gene therapy with a tumor-targeting peptide carrier can activate multiple cancer-fighting pathways simultaneously, aligning with the broader trend toward multi-mechanism cancer treatments.

This is an in vitro study using a single breast cancer cell line (MCF7), which may not represent the heterogeneity of breast cancers in patients. No in vivo experiments or animal models were used. The study builds heavily on prior work for construct design and nanocarrier optimization, making it difficult to assess as a standalone study. Specific fold-change values for gene expression increases are not reported in the abstract. No comparison with other delivery systems was included.